Apellis Pharmaceuticals (NASDAQ:APLS) PT Lowered to $57.00

Apellis Pharmaceuticals (NASDAQ:APLSFree Report) had its target price decreased by Wedbush from $67.00 to $57.00 in a research note issued to investors on Wednesday, Benzinga reports. Wedbush currently has a neutral rating on the stock. Wedbush also issued estimates for Apellis Pharmaceuticals’ Q1 2024 earnings at ($0.83) EPS, Q4 2024 earnings at ($0.27) EPS, FY2024 earnings at ($2.18) EPS, FY2025 earnings at $2.23 EPS, FY2026 earnings at $4.50 EPS, FY2027 earnings at $6.53 EPS and FY2028 earnings at $8.24 EPS.

Several other analysts have also weighed in on APLS. Raymond James upped their price objective on Apellis Pharmaceuticals from $67.00 to $106.00 and gave the company a strong-buy rating in a report on Thursday, January 11th. Needham & Company LLC restated a buy rating and issued a $85.00 price target on shares of Apellis Pharmaceuticals in a research report on Tuesday, April 9th. Mizuho restated a neutral rating and issued a $60.00 target price on shares of Apellis Pharmaceuticals in a report on Wednesday, March 27th. JPMorgan Chase & Co. increased their price target on Apellis Pharmaceuticals from $78.00 to $79.00 and gave the company an overweight rating in a research report on Wednesday, March 6th. Finally, Jefferies Financial Group upgraded Apellis Pharmaceuticals from a hold rating to a buy rating and boosted their price objective for the stock from $68.00 to $80.00 in a report on Monday, February 5th. Three investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and a consensus target price of $77.93.

Get Our Latest Report on Apellis Pharmaceuticals

Apellis Pharmaceuticals Trading Up 0.0 %

Shares of APLS stock opened at $47.53 on Wednesday. Apellis Pharmaceuticals has a 1 year low of $19.83 and a 1 year high of $94.75. The firm has a market capitalization of $5.73 billion, a PE ratio of -10.61 and a beta of 0.88. The stock has a fifty day moving average of $59.71 and a two-hundred day moving average of $57.04. The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.50 and a current ratio of 3.10.

Apellis Pharmaceuticals (NASDAQ:APLSGet Free Report) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($0.73) earnings per share for the quarter, hitting the consensus estimate of ($0.73). The business had revenue of $146.38 million during the quarter, compared to the consensus estimate of $143.34 million. Apellis Pharmaceuticals had a negative net margin of 133.34% and a negative return on equity of 178.60%. The company’s quarterly revenue was up 545.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.50) earnings per share. As a group, research analysts expect that Apellis Pharmaceuticals will post -1.33 EPS for the current year.

Insiders Place Their Bets

In related news, insider Pascal Deschatelets sold 69,107 shares of the stock in a transaction on Monday, April 8th. The stock was sold at an average price of $54.17, for a total transaction of $3,743,526.19. Following the completion of the sale, the insider now directly owns 1,115,983 shares in the company, valued at $60,452,799.11. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other Apellis Pharmaceuticals news, CFO Timothy Eugene Sullivan sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $58.66, for a total value of $234,640.00. Following the completion of the sale, the chief financial officer now directly owns 93,338 shares of the company’s stock, valued at $5,475,207.08. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Pascal Deschatelets sold 69,107 shares of the firm’s stock in a transaction on Monday, April 8th. The shares were sold at an average price of $54.17, for a total transaction of $3,743,526.19. Following the transaction, the insider now owns 1,115,983 shares in the company, valued at approximately $60,452,799.11. The disclosure for this sale can be found here. Insiders sold a total of 406,651 shares of company stock worth $25,130,257 in the last quarter. 7.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Several institutional investors have recently bought and sold shares of APLS. Cim Investment Management Inc. grew its holdings in Apellis Pharmaceuticals by 3.6% during the first quarter. Cim Investment Management Inc. now owns 4,744 shares of the company’s stock valued at $313,000 after purchasing an additional 163 shares during the last quarter. Sippican Capital Advisors grew its position in shares of Apellis Pharmaceuticals by 1.1% in the fourth quarter. Sippican Capital Advisors now owns 16,004 shares of the company’s stock valued at $958,000 after purchasing an additional 170 shares during the last quarter. Advisor Group Holdings Inc. lifted its position in shares of Apellis Pharmaceuticals by 6.9% during the 4th quarter. Advisor Group Holdings Inc. now owns 3,249 shares of the company’s stock worth $167,000 after purchasing an additional 209 shares during the last quarter. Treasurer of the State of North Carolina boosted its stake in Apellis Pharmaceuticals by 0.5% during the 3rd quarter. Treasurer of the State of North Carolina now owns 43,800 shares of the company’s stock valued at $1,666,000 after purchasing an additional 230 shares during the period. Finally, First Horizon Advisors Inc. grew its holdings in Apellis Pharmaceuticals by 69.0% in the 3rd quarter. First Horizon Advisors Inc. now owns 649 shares of the company’s stock valued at $25,000 after buying an additional 265 shares during the last quarter. 96.29% of the stock is currently owned by institutional investors.

Apellis Pharmaceuticals Company Profile

(Get Free Report)

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).

Recommended Stories

Analyst Recommendations for Apellis Pharmaceuticals (NASDAQ:APLS)

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.